首页 > 最新文献

Dementia and neurocognitive disorders最新文献

英文 中文
Comment: Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review. 评论:新冠肺炎疫苗接种后脑炎是亚急性进展性痴呆的原因:病例报告和文献综述。
Pub Date : 2023-07-01 Epub Date: 2023-07-07 DOI: 10.12779/dnd.2023.22.3.112
Amnuay Kleebayoon, Viroj Wiwanitkit
We would like to share ideas on the publication “Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review.1” Jung et al.1 reported an unusual occurrence of vaccination-induced encephalitis in a patient with dementia. According to Jung et al.,1 we should thoroughly assess older individuals who have cognitive deficits and take their histories to rule out reversible causes. The authors advised that clinicians should take autoimmune encephalitis into account as a potential diagnosis when evaluating post-vaccination neurologic symptoms and subacute dementia.1
{"title":"Comment: Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review.","authors":"Amnuay Kleebayoon, Viroj Wiwanitkit","doi":"10.12779/dnd.2023.22.3.112","DOIUrl":"10.12779/dnd.2023.22.3.112","url":null,"abstract":"We would like to share ideas on the publication “Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review.1” Jung et al.1 reported an unusual occurrence of vaccination-induced encephalitis in a patient with dementia. According to Jung et al.,1 we should thoroughly assess older individuals who have cognitive deficits and take their histories to rule out reversible causes. The authors advised that clinicians should take autoimmune encephalitis into account as a potential diagnosis when evaluating post-vaccination neurologic symptoms and subacute dementia.1","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 3","pages":"112-113"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/2d/dnd-22-112.PMC10400343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9943346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Education on Discriminability of Montreal Cognitive Assessment Compared to Mini-Mental State Examination. 教育对蒙特利尔认知评估与小型精神状态检查的可辨别性的影响。
Pub Date : 2023-04-01 Epub Date: 2023-04-30 DOI: 10.12779/dnd.2023.22.2.69
Haeyoon Kim, Seonyeong Yang, Jaesel Park, Byeong Chae Kim, Kyung-Ho Yu, Yeonwook Kang

Background and purpose: The Montreal Cognitive Assessment (MoCA) has been known as a screening test for detecting mild cognitive impairment (MCI) better than Mini-Mental State Examination (MMSE). However, in previous domestic studies, no significant difference was found in the discriminability between MoCA and MMSE. Researchers have suggested that this might be because older Koreans are less educated than older Westerners. This study was conducted to examine the effect of education on the discriminability of MoCA compared to the MMSE.

Methods: Participants were 123 cognitively normal elderly, 118 with vascular MCI, 108 with amnestic MCI, 121 with vascular dementia, and 113 with dementia of the Alzheimer's type. The Korean-MoCA (K-MoCA) and Korean-MMSE (K-MMSE) were administered. Multiple regression analyses and receiver operating characteristic (ROC) curve analyses were performed.

Results: In all participants, education significantly affected both K-MoCA and K-MMSE scores along with age. The effect of education was re-examined by subgroup analysis after dividing subjects according to the level of education. Effect of education on K-MoCA and K-MMSE was only shown in the group with <9 years of education. ROC curve analyses revealed that the discriminability of K-MoCA to differentiate between vascular MCI and normal elderly was significantly higher than that of K-MMSE. When re-examining subgroups divided by education level, however, this higher discriminability of K-MoCA disappeared in the group with <9 years of education.

Conclusions: These results indicate no difference in discriminating cognitive deficits between K-MoCA and K-MMSE in Korean elderly with <9 years of education.

背景和目的:蒙特利尔认知评估(MoCA)被认为是一种比简易精神状态检查(MMSE)更好地检测轻度认知障碍(MCI)的筛查测试。然而,在以前的国内研究中,MoCA和MMSE的可分辨性没有发现显著差异。研究人员认为,这可能是因为年长的韩国人受教育程度低于年长的西方人。与MMSE相比,本研究旨在检验教育对MoCA辨别能力的影响。方法:参与者包括123名认知正常的老年人、118名血管性MCI患者、108名失忆性MCI、121名血管性痴呆患者和113名阿尔茨海默型痴呆患者。给予韩国MoCA(K-MoCA)和韩国MMSE(K-MMSE)。进行多元回归分析和受试者工作特性(ROC)曲线分析。结果:在所有参与者中,教育程度随着年龄的增长显著影响K-MoCA和K-MMSE评分。根据教育水平划分科目后,通过亚组分析重新检验教育效果。教育对K-MoCA和K-MMSE的影响仅在以下组中显示:这些结果表明,在韩国老年人中,K-MoCA与K-MMSE在辨别认知缺陷方面没有差异
{"title":"Effect of Education on Discriminability of Montreal Cognitive Assessment Compared to Mini-Mental State Examination.","authors":"Haeyoon Kim,&nbsp;Seonyeong Yang,&nbsp;Jaesel Park,&nbsp;Byeong Chae Kim,&nbsp;Kyung-Ho Yu,&nbsp;Yeonwook Kang","doi":"10.12779/dnd.2023.22.2.69","DOIUrl":"10.12779/dnd.2023.22.2.69","url":null,"abstract":"<p><strong>Background and purpose: </strong>The Montreal Cognitive Assessment (MoCA) has been known as a screening test for detecting mild cognitive impairment (MCI) better than Mini-Mental State Examination (MMSE). However, in previous domestic studies, no significant difference was found in the discriminability between MoCA and MMSE. Researchers have suggested that this might be because older Koreans are less educated than older Westerners. This study was conducted to examine the effect of education on the discriminability of MoCA compared to the MMSE.</p><p><strong>Methods: </strong>Participants were 123 cognitively normal elderly, 118 with vascular MCI, 108 with amnestic MCI, 121 with vascular dementia, and 113 with dementia of the Alzheimer's type. The Korean-MoCA (K-MoCA) and Korean-MMSE (K-MMSE) were administered. Multiple regression analyses and receiver operating characteristic (ROC) curve analyses were performed.</p><p><strong>Results: </strong>In all participants, education significantly affected both K-MoCA and K-MMSE scores along with age. The effect of education was re-examined by subgroup analysis after dividing subjects according to the level of education. Effect of education on K-MoCA and K-MMSE was only shown in the group with <9 years of education. ROC curve analyses revealed that the discriminability of K-MoCA to differentiate between vascular MCI and normal elderly was significantly higher than that of K-MMSE. When re-examining subgroups divided by education level, however, this higher discriminability of K-MoCA disappeared in the group with <9 years of education.</p><p><strong>Conclusions: </strong>These results indicate no difference in discriminating cognitive deficits between K-MoCA and K-MMSE in Korean elderly with <9 years of education.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/bf/dnd-22-69.PMC10166679.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Classification of Aβ State From Brain Amyloid PET Images Using Machine Learning Algorithm. 利用机器学习算法对脑淀粉样PET图像中Aβ状态的分类。
Pub Date : 2023-04-01 Epub Date: 2023-04-30 DOI: 10.12779/dnd.2023.22.2.61
Chanda Simfukwe, Reeree Lee, Young Chul Youn

Background and purpose: Analyzing brain amyloid positron emission tomography (PET) images to access the occurrence of β-amyloid (Aβ) deposition in Alzheimer's patients requires much time and effort from physicians, while the variation of each interpreter may differ. For these reasons, a machine learning model was developed using a convolutional neural network (CNN) as an objective decision to classify the Aβ positive and Aβ negative status from brain amyloid PET images.

Methods: A total of 7,344 PET images of 144 subjects were used in this study. The 18F-florbetaben PET was administered to all participants, and the criteria for differentiating Aβ positive and Aβ negative state was based on brain amyloid plaque load score (BAPL) that depended on the visual assessment of PET images by the physicians. We applied the CNN algorithm trained in batches of 51 PET images per subject directory from 2 classes: Aβ positive and Aβ negative states, based on the BAPL scores.

Results: The binary classification of the model average performance matrices was evaluated after 40 epochs of three trials based on test datasets. The model accuracy for classifying Aβ positivity and Aβ negativity was (95.00±0.02) in the test dataset. The sensitivity and specificity were (96.00±0.02) and (94.00±0.02), respectively, with an area under the curve of (87.00±0.03).

Conclusions: Based on this study, the designed CNN model has the potential to be used clinically to screen amyloid PET images.

背景和目的:分析阿尔茨海默病患者大脑淀粉样蛋白正电子发射断层扫描(PET)图像以了解β-淀粉样蛋白(Aβ)沉积的发生情况需要医生花费大量时间和精力,而每个口译员的变化可能不同。出于这些原因,使用卷积神经网络(CNN)开发了一个机器学习模型,作为从大脑淀粉样蛋白PET图像中对aβ阳性和aβ阴性状态进行分类的客观决策。方法:本研究共使用了144名受试者的7344张PET图像。所有参与者均接受18F氟苯PET,区分Aβ阳性和Aβ阴性状态的标准基于脑淀粉样斑块负荷评分(BAPL),该评分取决于医生对PET图像的视觉评估。我们应用CNN算法,根据BAPL评分,对来自两个类别(Aβ阳性和Aβ阴性)的每个受试者目录的51张PET图像进行批量训练。结果:在基于测试数据集的三次试验的40个时期后,对模型平均性能矩阵的二元分类进行了评估。在测试数据集中,Aβ阳性和Aβ阴性分类的模型准确度为(95.00±0.02)。其敏感性和特异性分别为(96.00±0.02)和(94.00±0.02%),曲线下面积为(87.00±0.03)。结论:基于本研究,所设计的CNN模型具有临床筛选淀粉样蛋白PET图像的潜力。
{"title":"Classification of Aβ State From Brain Amyloid PET Images Using Machine Learning Algorithm.","authors":"Chanda Simfukwe,&nbsp;Reeree Lee,&nbsp;Young Chul Youn","doi":"10.12779/dnd.2023.22.2.61","DOIUrl":"10.12779/dnd.2023.22.2.61","url":null,"abstract":"<p><strong>Background and purpose: </strong>Analyzing brain amyloid positron emission tomography (PET) images to access the occurrence of β-amyloid (Aβ) deposition in Alzheimer's patients requires much time and effort from physicians, while the variation of each interpreter may differ. For these reasons, a machine learning model was developed using a convolutional neural network (CNN) as an objective decision to classify the Aβ positive and Aβ negative status from brain amyloid PET images.</p><p><strong>Methods: </strong>A total of 7,344 PET images of 144 subjects were used in this study. The 18F-florbetaben PET was administered to all participants, and the criteria for differentiating Aβ positive and Aβ negative state was based on brain amyloid plaque load score (BAPL) that depended on the visual assessment of PET images by the physicians. We applied the CNN algorithm trained in batches of 51 PET images per subject directory from 2 classes: Aβ positive and Aβ negative states, based on the BAPL scores.</p><p><strong>Results: </strong>The binary classification of the model average performance matrices was evaluated after 40 epochs of three trials based on test datasets. The model accuracy for classifying Aβ positivity and Aβ negativity was (95.00±0.02) in the test dataset. The sensitivity and specificity were (96.00±0.02) and (94.00±0.02), respectively, with an area under the curve of (87.00±0.03).</p><p><strong>Conclusions: </strong>Based on this study, the designed CNN model has the potential to be used clinically to screen amyloid PET images.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"61-68"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/2f/dnd-22-61.PMC10166673.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9821300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review. 新冠肺炎疫苗接种后脑炎是亚急性进展性痴呆的原因:病例报告和文献回顾。
Pub Date : 2023-04-01 Epub Date: 2023-04-30 DOI: 10.12779/dnd.2023.22.2.81
Heui-Seop Jung, Yun Jeong Hong, Seong Hoon Kim, Yun Sang Oh, Si Baek Lee, Myung Ah Lee, Jeong Wook Park
The coronavirus disease 2019 (COVID-19) pandemic has caused more than 500 million infected cases, causing a new public health crisis.1 Many people are vaccinated against COVID-19 to prevent infection and bring an end to the pandemic. However, various complications have been reported.1,2 Autoimmune encephalitis is a progressive encephalopathy that can develop rapidly (usually in less than 6 weeks) caused by brain inflammation.3 In this case report, we present a rare case of a 59-year-old woman who visited an outpatient clinic because of subacute onset cognitive decline. She was diagnosed with post COVID-19 vaccination encephalitis. We observed 1-year cognitive outcomes and neuroimaging changes of the patient. Clinical, neuroimaging, and cerebrospinal fluid (CSF) findings of the patient are described below.
{"title":"Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review.","authors":"Heui-Seop Jung,&nbsp;Yun Jeong Hong,&nbsp;Seong Hoon Kim,&nbsp;Yun Sang Oh,&nbsp;Si Baek Lee,&nbsp;Myung Ah Lee,&nbsp;Jeong Wook Park","doi":"10.12779/dnd.2023.22.2.81","DOIUrl":"10.12779/dnd.2023.22.2.81","url":null,"abstract":"The coronavirus disease 2019 (COVID-19) pandemic has caused more than 500 million infected cases, causing a new public health crisis.1 Many people are vaccinated against COVID-19 to prevent infection and bring an end to the pandemic. However, various complications have been reported.1,2 Autoimmune encephalitis is a progressive encephalopathy that can develop rapidly (usually in less than 6 weeks) caused by brain inflammation.3 In this case report, we present a rare case of a 59-year-old woman who visited an outpatient clinic because of subacute onset cognitive decline. She was diagnosed with post COVID-19 vaccination encephalitis. We observed 1-year cognitive outcomes and neuroimaging changes of the patient. Clinical, neuroimaging, and cerebrospinal fluid (CSF) findings of the patient are described below.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"81-83"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/c7/dnd-22-81.PMC10166676.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10299786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Erratum: A Comparison Between the Performances of Verbal and Nonverbal Fluency Tests in Discriminating Between Mild Cognitive Impairments and Alzheimer's Disease Patients and Their Brain Morphological Correlates. 勘误表:言语和非言语流利性测试在区分轻度认知障碍和阿尔茨海默病患者方面的表现及其大脑形态学相关性的比较。
Pub Date : 2023-04-01 Epub Date: 2023-04-27 DOI: 10.12779/dnd.2023.22.2.85
Seyul Kwak, Seong A Shin, Hyunwoong Ko, Hairin Kim, Dae Jong Oh, Jung Hae Youn, Jun-Young Lee, Yu Kyeong Kim

[This corrects the article on p. 17 in vol. 21, PMID: 35154337.].

[这更正了第21卷第17页的文章,PMID:35154337.]。
{"title":"Erratum: A Comparison Between the Performances of Verbal and Nonverbal Fluency Tests in Discriminating Between Mild Cognitive Impairments and Alzheimer's Disease Patients and Their Brain Morphological Correlates.","authors":"Seyul Kwak,&nbsp;Seong A Shin,&nbsp;Hyunwoong Ko,&nbsp;Hairin Kim,&nbsp;Dae Jong Oh,&nbsp;Jung Hae Youn,&nbsp;Jun-Young Lee,&nbsp;Yu Kyeong Kim","doi":"10.12779/dnd.2023.22.2.85","DOIUrl":"10.12779/dnd.2023.22.2.85","url":null,"abstract":"<p><p>[This corrects the article on p. 17 in vol. 21, PMID: 35154337.].</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"85"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/89/dnd-22-85.PMC10166678.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9462393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-LGI1 Encephalitis Presented With Prominent Psychosis Without Loss of Consciousness. 抗-LGI1型脑炎伴明显精神病且无意识丧失。
Pub Date : 2023-04-01 Epub Date: 2023-04-27 DOI: 10.12779/dnd.2023.22.2.78
Ja Hyeon Cho, Sun Jung Kim, Kyung Won Park
elevation of protein (white blood cell [WBC]: 3 mm 3 , protein: 92 mg/dL, glucose: 81 mg/dL, virus/bacteria polymerase chain reaction [PCR]: all negative). Tests for anti-LGI1 antibody in CSF and blood tests were positive. Thus, anti-LGI1 encephalitis was diagnosed. A steroid pulse therapy for 5 days was done initially. Right after steroid pulse therapy, intravenous immunoglobulin therapy for 5 days was done. At 11 days after treatment with steroid pulse and intravenous immunoglobulin therapies, the patient’s cognitive and psychiatric symptoms returned to his previous levels. In MMSE, he scored 30. No SNSB test was performed after treatment because neither the patient nor caregivers complained of any symptoms
{"title":"Anti-LGI1 Encephalitis Presented With Prominent Psychosis Without Loss of Consciousness.","authors":"Ja Hyeon Cho,&nbsp;Sun Jung Kim,&nbsp;Kyung Won Park","doi":"10.12779/dnd.2023.22.2.78","DOIUrl":"10.12779/dnd.2023.22.2.78","url":null,"abstract":"elevation of protein (white blood cell [WBC]: 3 mm 3 , protein: 92 mg/dL, glucose: 81 mg/dL, virus/bacteria polymerase chain reaction [PCR]: all negative). Tests for anti-LGI1 antibody in CSF and blood tests were positive. Thus, anti-LGI1 encephalitis was diagnosed. A steroid pulse therapy for 5 days was done initially. Right after steroid pulse therapy, intravenous immunoglobulin therapy for 5 days was done. At 11 days after treatment with steroid pulse and intravenous immunoglobulin therapies, the patient’s cognitive and psychiatric symptoms returned to his previous levels. In MMSE, he scored 30. No SNSB test was performed after treatment because neither the patient nor caregivers complained of any symptoms","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"78-80"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/27/dnd-22-78.PMC10166675.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9821303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure. 勘误表:有橙剂暴露史的阿尔茨海默病患者的血浆低聚β淀粉样蛋白。
Pub Date : 2023-04-01 Epub Date: 2023-04-06 DOI: 10.12779/dnd.2023.22.2.84
YoungSoon Yang, Vo Van Giau, Seong Soo A An, SangYun Kim

[This corrects the article on p. 41 in vol. 17, PMID: 30906391.].

[这更正了第17卷第41页的文章,PMID:30906391。]。
{"title":"Erratum: Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure.","authors":"YoungSoon Yang,&nbsp;Vo Van Giau,&nbsp;Seong Soo A An,&nbsp;SangYun Kim","doi":"10.12779/dnd.2023.22.2.84","DOIUrl":"10.12779/dnd.2023.22.2.84","url":null,"abstract":"<p><p>[This corrects the article on p. 41 in vol. 17, PMID: 30906391.].</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"84"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/75/dnd-22-84.PMC10166677.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9462392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dementia Incidence Rate Before and After Implementing the National Responsibility Policy for Dementia Care in Patients With Vascular Risk Factors in Korea. 韩国实施血管危险因素患者痴呆症护理国家责任政策前后的痴呆症发病率。
Pub Date : 2023-04-01 Epub Date: 2023-04-14 DOI: 10.12779/dnd.2023.22.2.49
Gihwan Byeon, Sung Ok Kwon, JinHyeong Jhoo, Jae-Won Jang, Yeshin Kim

Background and purpose: The National Responsibility Policy for Dementia Care was implemented in September 2017 in Korea. This study aimed to compare dementia incidence in Seoul and Gangwon-do before and after the implementation of this policy.

Methods: We extracted insurance claim data from the Korean Health Insurance Review and Assessment Service for people diagnosed with diabetes, hypertension, or dyslipidemia for the first time in Seoul and Gangwon-do, Korea. We defined two enrollment groups based on the policy implementation date: 1) January 1, 2015 to December 31, 2016 (Index 1, pre-implementation), and 2) January 1, 2017 to December 31, 2018 (Index 2, post-implementation). Each group was followed up for 1 year from the time of enrollment. Then, we calculated hazard ratios to compare the incidence of dementia between the two groups, and between Seoul and Gangwon-do.

Results: In Seoul, the incidence of dementia was significantly lower in Index 2 than in Index 1 (hazard ratio [HR], 0.926; 95% confidence interval [CI], 0.875-0.979). However, the incidence rate did not differ between the 2 groups (HR, 1.113; 95% CI, 0.966-1.281) in Gangwon-do. In Index 1, the incidence of dementia did not differ between Seoul and Gangwon-do (HR, 1.043; 95% CI, 0.941-1.156), but in Index 2, was significantly higher in Gangwon-do than in Seoul (HR, 1.240; 95% CI, 1.109-1.386).

Conclusions: After implementing the National Responsibility Policy for Dementia Care, the dementia incidence rate decreased significantly in Seoul, consistent with other studies, but not in Gangwon-do.

背景和目的:国家痴呆症护理责任政策于2017年9月在韩国实施。本研究旨在比较该政策实施前后首尔和江原道的痴呆症发病率。方法:我们从韩国健康保险审查和评估服务中心提取了在韩国首尔和江原道首次诊断为糖尿病、高血压或血脂异常的人的保险索赔数据。我们根据政策实施日期定义了两个招生组:1)2015年1月1日至2016年12月31日(指标1,实施前);2)2017年1月31日至2018年12月30日(指标2,实施后)。每组从入组时起随访1年。然后,我们计算了风险比,以比较两组之间以及首尔和江原道之间的痴呆症发病率。结果:在首尔,指数2的痴呆症发病率显著低于指数1(危险比[HR],0.926;95%置信区间[CI],0.875-0.979)。然而,江原道两组的发病率没有差异(HR,1.113;95%CI,0.966-1.281)。在指数1中,首尔和江原道的痴呆症发病率没有差异(HR,1.043;95%CI,0.941-1.156),但在指数2中,江原道显著高于首尔(HR,1.240;95%CI为1.109-1.386),但江原道没有。
{"title":"Dementia Incidence Rate Before and After Implementing the National Responsibility Policy for Dementia Care in Patients With Vascular Risk Factors in Korea.","authors":"Gihwan Byeon,&nbsp;Sung Ok Kwon,&nbsp;JinHyeong Jhoo,&nbsp;Jae-Won Jang,&nbsp;Yeshin Kim","doi":"10.12779/dnd.2023.22.2.49","DOIUrl":"10.12779/dnd.2023.22.2.49","url":null,"abstract":"<p><strong>Background and purpose: </strong>The National Responsibility Policy for Dementia Care was implemented in September 2017 in Korea. This study aimed to compare dementia incidence in Seoul and Gangwon-do before and after the implementation of this policy.</p><p><strong>Methods: </strong>We extracted insurance claim data from the Korean Health Insurance Review and Assessment Service for people diagnosed with diabetes, hypertension, or dyslipidemia for the first time in Seoul and Gangwon-do, Korea. We defined two enrollment groups based on the policy implementation date: 1) January 1, 2015 to December 31, 2016 (Index 1, pre-implementation), and 2) January 1, 2017 to December 31, 2018 (Index 2, post-implementation). Each group was followed up for 1 year from the time of enrollment. Then, we calculated hazard ratios to compare the incidence of dementia between the two groups, and between Seoul and Gangwon-do.</p><p><strong>Results: </strong>In Seoul, the incidence of dementia was significantly lower in Index 2 than in Index 1 (hazard ratio [HR], 0.926; 95% confidence interval [CI], 0.875-0.979). However, the incidence rate did not differ between the 2 groups (HR, 1.113; 95% CI, 0.966-1.281) in Gangwon-do. In Index 1, the incidence of dementia did not differ between Seoul and Gangwon-do (HR, 1.043; 95% CI, 0.941-1.156), but in Index 2, was significantly higher in Gangwon-do than in Seoul (HR, 1.240; 95% CI, 1.109-1.386).</p><p><strong>Conclusions: </strong>After implementing the National Responsibility Policy for Dementia Care, the dementia incidence rate decreased significantly in Seoul, consistent with other studies, but not in Gangwon-do.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"22 2","pages":"49-60"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/30/dnd-22-49.PMC10166674.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Tablet-based Cognitive Intervention on Cognition in Patients With Mild Cognitive Impairment: A Pilot Study 基于片剂的认知干预对轻度认知障碍患者认知的影响:一项初步研究
Pub Date : 2023-01-01 DOI: 10.12779/dnd.2023.22.4.130
Ji Young Park, Seon Ae Choi, Jae Joon Kim, Yu Jeong Park, Chi Kyung Kim, Geum Joon Cho, Seong-Beom Koh, Sung Hoon Kang
Background and Purpose Growing evidence has shown that cognitive interventions can mitigate cognitive decline in patients with mild cognitive impairment (MCI). However, most previous cognitive interventions have been group-based programs. Due to their intrinsic limitations, group-based programs are not widely used in clinical practice. Therefore, we have developed a tablet-based cognitive intervention program. This preliminary study investigated the feasibility and effects of a 12-week structured tablet-based program on cognitive function in patients with MCI. Methods We performed a single-arm study on 24 patients with MCI. The participants underwent a tablet-based cognitive intervention program 5 times a week over a 12-week period. The primary outcome was changes in cognitive function, measured using the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K). Outcomes were evaluated at baseline, within two weeks of the last program (post-intervention), and at the six-month follow-up session. Results The completion rate of the tablet-based program was 83.3% in patients with MCI. The program improved cognitive function based on the CERAD-K total score (p=0.026), which was maintained for at least three months (p=0.004). There was also an improvement in the depression scale score (p=0.002), which persisted for three months (p=0.027). Conclusions Our 12-week structured tablet-based program is feasible for patients with MCI. Furthermore, although further studies with a double-arm design are required, the program appears to be an effective strategy to prevent cognitive decline in patients with MCI.
{"title":"Effect of Tablet-based Cognitive Intervention on Cognition in Patients With Mild Cognitive Impairment: A Pilot Study","authors":"Ji Young Park, Seon Ae Choi, Jae Joon Kim, Yu Jeong Park, Chi Kyung Kim, Geum Joon Cho, Seong-Beom Koh, Sung Hoon Kang","doi":"10.12779/dnd.2023.22.4.130","DOIUrl":"https://doi.org/10.12779/dnd.2023.22.4.130","url":null,"abstract":"Background and Purpose Growing evidence has shown that cognitive interventions can mitigate cognitive decline in patients with mild cognitive impairment (MCI). However, most previous cognitive interventions have been group-based programs. Due to their intrinsic limitations, group-based programs are not widely used in clinical practice. Therefore, we have developed a tablet-based cognitive intervention program. This preliminary study investigated the feasibility and effects of a 12-week structured tablet-based program on cognitive function in patients with MCI. Methods We performed a single-arm study on 24 patients with MCI. The participants underwent a tablet-based cognitive intervention program 5 times a week over a 12-week period. The primary outcome was changes in cognitive function, measured using the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K). Outcomes were evaluated at baseline, within two weeks of the last program (post-intervention), and at the six-month follow-up session. Results The completion rate of the tablet-based program was 83.3% in patients with MCI. The program improved cognitive function based on the CERAD-K total score (p=0.026), which was maintained for at least three months (p=0.004). There was also an improvement in the depression scale score (p=0.002), which persisted for three months (p=0.027). Conclusions Our 12-week structured tablet-based program is feasible for patients with MCI. Furthermore, although further studies with a double-arm design are required, the program appears to be an effective strategy to prevent cognitive decline in patients with MCI.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135667372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Persistent Treatment of Alzheimer’s Dementia and Osteoporosis Using a Common Data Model 长期治疗阿尔茨海默氏痴呆与骨质疏松症之间的关系
Pub Date : 2023-01-01 DOI: 10.12779/dnd.2023.22.4.121
Seonhwa Hwang, Yong Gwon Soung, Seong Uk Kang, Donghan Yu, Haeran Baek, Jae-Won Jang
Background and Purpose As it becomes an aging society, interest in senile diseases is increasing. Alzheimer’s dementia (AD) and osteoporosis are representative senile diseases. Various studies have reported that AD and osteoporosis share many risk factors that affect each other’s incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis. Methods The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership–Common Data Model version 5 format. Results This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09–1.32]; p<0.001). Conclusions We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.
{"title":"Association Between Persistent Treatment of Alzheimer’s Dementia and Osteoporosis Using a Common Data Model","authors":"Seonhwa Hwang, Yong Gwon Soung, Seong Uk Kang, Donghan Yu, Haeran Baek, Jae-Won Jang","doi":"10.12779/dnd.2023.22.4.121","DOIUrl":"https://doi.org/10.12779/dnd.2023.22.4.121","url":null,"abstract":"Background and Purpose As it becomes an aging society, interest in senile diseases is increasing. Alzheimer’s dementia (AD) and osteoporosis are representative senile diseases. Various studies have reported that AD and osteoporosis share many risk factors that affect each other’s incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis. Methods The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership–Common Data Model version 5 format. Results This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09–1.32]; p<0.001). Conclusions We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135667373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dementia and neurocognitive disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1